Novo Nordisk pushed the oralization of its GLP-1 platform into the clinic this year with a tablet version of Wegovy and competitors are closing in. Eli Lilly’s oral orforglipron is expected to clear regulators imminently, marking a shift from injectable-only obesity therapies to mass-market oral options. New data reviewed across trials show a consistent pattern of partial weight regain after stopping GLP-1 receptor agonists: patients regain most lost weight but typically plateau below their starting weight. That suggests sustained behavioral or physiological changes may persist but durable, drug‑free remission of obesity is uncommon. GLP-1 receptor agonists act on gut-brain incretin pathways to suppress appetite and improve glucose control; oral formulations will broaden access and alter payer strategies for obesity care. Industry players and payers are now recalibrating clinical expectations and commercial plans as pills enter the market.